Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort
Authors:
Open Access
- 10 March 2025
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (4) , 1589-1596
Abstract
Objectives: Anti-CD74 antibodies (Abs) have been proposed as a diagnostic biomarker in axial spondyloarthritis (axSpA). The aims of this study were to evaluate the association of these Abs with disease activity parameters in axSpA and to assess their predictive value for tumour necrosis factor inhibitor (TNFi) treatment effectiveness. Methods: Patients diagnosed with axSpA in the Swiss Clinical Quality Management registry with available biosamples and a measurement of IgA anti-CD74 Abs were included in this cohort study. We used a cut-off of 15 U/ml to define anti-CD74 Abs elevation. Associations of important disease characteristics with anti-CD4 Abs elevation and anti-CD74 Abs levels were evaluated using logistic and linear regression, respectively. For patients with an available biosample before TNFi initiation, we evaluated drug retention and estimated the hazard ratio of treatment discontinuation depending on anti-CD74 Abs elevation. Results: Elevated IgA anti-CD74 Abs were found in 383/722 (53%) patients with axSpA and were significantly associated with older age, male sex, and elevated C-reactive protein (CRP). Among 310 patients starting TNFi treatment, no significant difference in drug retention was found between patients with and without elevated anti-CD74 Abs (HR 0.91, 95% CI 0.66 to 1.25). An increased Bath Ankylosing Spondylitis Disease Activity Index was found to be associated with a reduced TNFi retention whereas an elevated CRP was associated with a prolonged retention. Conclusions: Although elevated IgA anti-CD74 Abs are associated with CRP elevation, we could not demonstrate an additional value of this biomarker for predicting response to treatment with TNFi beyond CRP measurement. Key Points• Elevated IgA anti-CD74 antibodies are associated with raised CRP• Elevated IgA anti-CD74 antibodies are not associated with prolonged TNF inhibitor retention after covariate-adjustmentKeywords
Funding Information
- University of Zurich
This publication has 21 references indexed in Scilit:
- Challenges in the diagnosis of axial spondyloarthritisBest Practice & Research Clinical Rheumatology, 2023
- Treatment overview of axial spondyloarthritis in 2023Best Practice & Research Clinical Rheumatology, 2023
- Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life ResultsAmerican Journal of Ophthalmology, 2021
- Anti-CD74 antibodies in spondyloarthritis: A systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2021
- Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish studyRheumatology, 2020
- Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitisEuropean Journal of Immunology, 2020
- Diagnostic value of anti-CD74 antibodies in early and late axial spondyloarthritis and its relationship to disease activityRheumatology, 2020
- Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial SpondyloarthritisArthritis & Rheumatology, 2018
- Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing SpondylitisArthritis & Rheumatology, 2017
- Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational CohortArthritis & Rheumatism, 2013